BCDA News and Press, BioCardia Inc. From 04/12/22

3 Penny Stocks to Watch Ahead of the Stock Market Open Today After a less than stellar day of trading penny stocks on April 11th, investors have high hopes for today. In the past few weeks, anyone who has traded either penny stocks or blue chips is no stranger to volatility. [...

The U.S. Food and Drug Administration (FDA) approved BioCardia's (NASDAQ:BCDA) application seeking to start a  phase 1/2 trial of BCDA-04 in adult patients recovering from Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. The company said the approval of its investiga...

SUNNYVALE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the...

The following slide deck was published by BioCardia, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: BioCardia, Inc. 2022 Q1 - Results - Earnings Call Presentation

BioCardia, Inc. (BCDA) Q4 2021 Earnings Conference Call March 29, 2022 4:30 AM ET Company Participants Jules Abraham - Investor Relations, CORE IR Peter Altman - President & CEO David McClung - CFO Conference Call Participants Kumar Raja - Brookline Capital Markets Emanuela Branchetti - H...

BioCardia press release (NASDAQ:BCDA): FY GAAP EPS of -$0.75. Revenue of $1M (+566.7% Y/Y). Shares +0.94%. Company ended the year with cash and cash equivalents totaling $12.9M, providing runway through 2022. For further details see: BioCardia GAAP EPS of -$0.75, revenue of $1M

SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed i...

SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 3...

SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP® C...

SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, th...